Ethereum ETF Boost: Shiba Inu Soars Amid Memecoin Maniaby John Darbie 15.06.2024The Ethereum ETF’s impact on Shiba Inu (SHIB), rising institutional interest, and the surge in Solana's memecoins highlight crypto growth ...
Ethereum on Track to Shatter ATH, Analyst Predicts $8,348by John Darbie 15.06.2024Ethereum's path to an all-time high is unavoidable, with a potential breakout leading to a 75% gain. Meanwhile, Bitcoin faces ...
Madrigal Pharma Exec Sells $570K in Stock Amid Analyst Focusby Mark Eisenberg 15.06.2024Waltermire sells 2,000 shares at $285 each, netting $570K; Madrigal Pharmaceuticals sees mixed analyst reports with H.C. Wainwright lowering its ...
Avidity Biosciences CFO Sells $3.7M in Stock Amid Positive Newsby Terry Bingman 15.06.2024Avidity Biosciences sees share ownership shift as MacLean reduces holding under Rule 10b5-1 Plan; positive sector developments bolster outlook.
Avidity Biosciences Director Sells $3.8M in Stockby Mark Eisenberg 15.06.2024Arthur A. Levin sells 40K Avidity shares; BofA ups target to $45 as FDA advances myotonic dystrophy treatment. AI-assisted article ...
DallasNews Chief Invests $26K in Stock Amid Cash Woesby Mark Eisenberg 15.06.2024Murray acquires 7,000+ DallasNews shares; exacting prices and Q2 earnings update ahead amid cash burn and unprofitability concerns.
Tempus AI Raises $410M in IPO, Sees Revenue Surgeby Mark Eisenberg 15.06.2024Tempus AI sold 11M shares at $37 each, launched in 2015, focuses on medical testing, with revenue growth from $320.7M ...
Primoris Director Sells $209K in Shares Amid Growth Plansby Mark Eisenberg 15.06.2024Mashinski’s sale of shares valued at $209,371 adjusts her Primoris stake to 20,454 shares, per SEC Form 4. Primoris targets ...
Altimmune’s Promising GLP-1 Drug: Worth the Investment?by Mark Eisenberg 25.04.2024Altimmune's stock has seen a strong increase in value, surpassing Eli Lilly and Novo Nordisk. However, there are risks involved.
Elon Musk’s Companies Exchange $9M in Expensesby Mark Eisenberg 25.04.2024Tesla faces financial challenges as details about expenses are scarce and positive investor sentiment may be waning, despite efforts to ...